Loading clinical trials...

Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria | Clinical Trials | Clareo Health

COMPLETEDPhase 4NCT02633046

Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria

Focal segmental glomerulosclerosis (FSGS) is a condition that harms the kidney "filters" that remove waste from the blood. Proteins are supposed to stay in the blood. Damaged "filters" let protein get...

Lead sponsor: Mallinckrodt ARD LLC•21 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusCOMPLETED

PhasePHASE4

Enrollment63

Start dateOct 2016

Last updatedAug 4, 2021

Condition

Idiopathic Focal Segmental Glomerulosclerosis

Locations shown

University of Alabama at Birmingham

Birmingham, Alabama

AKDHC Medical Research Services, LLC

Tucson, Arizona

California Institute of Renal Research

Chula Vista, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 4, 2021Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions